Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Calmels

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Drug Discovery Today|January 11, 2018
From clinical proof-of-concept to commercialization of CAR T cellsBoris Calmels, Bechara Mfarrej, Christian Chabannon
The Journal of Biological Chemistry|June 26, 2002
The cleavage/polyadenylation activity triggered by a U-rich motif sequence is differently required depending on the poly(A) site location at either the first or last 3'-terminal exon of the 2'-5' oligo(A) synthetase geneYoussef Aissouni, Christophe Perez, Boris Calmels, et al.
Leukemia & Lymphoma|March 23, 2002
Ikaros gene expression and leukemiaCécile Tonnelle, Boris Calmels, Christine Maroc, et al.
Bulletin Du Cancer|August 13, 2011
[New molecular targets and new clinical practices for hematopoietic stem cell mobilization]Christian Chabannon, Boris Calmels, Sarah Habibi, et al.
Current Gene Therapy|November 1, 2007
Potential application of gene therapy to X-linked agammaglobulinemiaThomas Moreau, Boris Calmels, Vincent Barlogis, et al.
Cytotherapy|July 29, 2020
Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular productsBechara Mfarrej, Julie Gaude, Jerome Couquiaud, et al.
Cytotherapy|November 3, 2009
A new single-platform method for the enumeration of CD34+ cellsClaude Lemarie, Guillaume Bouchet, Isabelle Sielleur, et al.
Bulletin Du Cancer|November 12, 2003
[Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches]Mohamad Mohty, Béatrice Gaugler, Boris Calmels, et al.
Cytotherapy|July 2, 2019
Validation of a semi automatic device to standardize quantification of Colony-Forming Unit (CFU) on hematopoietic stem cell productsMélanie Velier, Anne-Line Chateau, Carine Malenfant, et al.
Frontiers in Immunology|November 30, 2016
Manufacturing Natural Killer Cells as Medicinal ProductsChristian Chabannon, Bechara Mfarrej, Sophie Guia, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Drug Discovery Today|January 11, 2018
From clinical proof-of-concept to commercialization of CAR T cellsBoris Calmels, Bechara Mfarrej, Christian Chabannon
The Journal of Biological Chemistry|June 26, 2002
The cleavage/polyadenylation activity triggered by a U-rich motif sequence is differently required depending on the poly(A) site location at either the first or last 3'-terminal exon of the 2'-5' oligo(A) synthetase geneYoussef Aissouni, Christophe Perez, Boris Calmels, et al.
Leukemia & Lymphoma|March 23, 2002
Ikaros gene expression and leukemiaCécile Tonnelle, Boris Calmels, Christine Maroc, et al.
Bulletin Du Cancer|August 13, 2011
[New molecular targets and new clinical practices for hematopoietic stem cell mobilization]Christian Chabannon, Boris Calmels, Sarah Habibi, et al.
Current Gene Therapy|November 1, 2007
Potential application of gene therapy to X-linked agammaglobulinemiaThomas Moreau, Boris Calmels, Vincent Barlogis, et al.
Cytotherapy|July 29, 2020
Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular productsBechara Mfarrej, Julie Gaude, Jerome Couquiaud, et al.
Cytotherapy|November 3, 2009
A new single-platform method for the enumeration of CD34+ cellsClaude Lemarie, Guillaume Bouchet, Isabelle Sielleur, et al.
Bulletin Du Cancer|November 12, 2003
[Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches]Mohamad Mohty, Béatrice Gaugler, Boris Calmels, et al.
Cytotherapy|July 2, 2019
Validation of a semi automatic device to standardize quantification of Colony-Forming Unit (CFU) on hematopoietic stem cell productsMélanie Velier, Anne-Line Chateau, Carine Malenfant, et al.
Frontiers in Immunology|November 30, 2016
Manufacturing Natural Killer Cells as Medicinal ProductsChristian Chabannon, Bechara Mfarrej, Sophie Guia, et al.
Pageof 7